Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Fanelli

Showing results (191-200 of 220) with videos related to

Pageof 22
Sort By:
Diabetes|March 20, 2010
Mechanisms of insulin resistance after insulin-induced hypoglycemia in humans: the role of lipolysisPaola Lucidi, Paolo Rossetti, Francesca Porcellati, et al.
Journal of Clinical Neurophysiology : Official Publication of the American Electroencephalographic Society|March 10, 2000
Computer-assisted EEG monitoring during carotid endarterectomyF Minicucci, M Cursi, C Fornara, et al.
Diabetes|October 15, 2008
Portal vein glucose sensors do not play a major role in modulating physiological responses to insulin-induced hypoglycemia in humansPaolo Rossetti, Francesca Porcellati, Paola Lucidi, et al.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|April 8, 2014
Glargine metabolism over 24 h following its subcutaneous injection in patients with type 2 diabetes mellitus: a dose-response studyP Lucidi, F Porcellati, P Candeloro, et al.
Diabetes Care|January 14, 2021
Pharmacokinetic and Pharmacodynamic Head-to-Head Comparison of Clinical, Equivalent Doses of Insulin Glargine 300 units · mL<sup>-1</sup> and Insulin Degludec 100 units · mL<sup>-1</sup> in Type 1 DiabetesPaola Lucidi, Paola Candeloro, Patrizia Cioli, et al.
Diabetologia|December 13, 2006
Effect of the amino acid alanine on glucagon secretion in non-diabetic and type 1 diabetic subjects during hyperinsulinaemic euglycaemia, hypoglycaemia and post-hypoglycaemic hyperglycaemiaF Porcellati, S Pampanelli, P Rossetti, et al.
The Journal of Clinical Endocrinology and Metabolism|May 28, 2009
Short-term effects of the long-acting insulin analog detemir and human insulin on plasma levels of insulin-like growth factor-I and its binding proteins in humansFrancesca Porcellati, Paolo Rossetti, Paola Candeloro, et al.
Diabetes Care|March 21, 2025
The Modern Role of Basal Insulin in Advancing Therapy in People With Type 2 DiabetesGeremia B Bolli, Philip D Home, Francesca Porcellati, et al.
Diabetes Care|July 12, 2007
Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover studyFrancesca Porcellati, Paolo Rossetti, Natalia Ricci Busciantella, et al.
Diabetes|April 9, 2008
Effect of oral amino acids on counterregulatory responses and cognitive function during insulin-induced hypoglycemia in nondiabetic and type 1 diabetic peoplePaolo Rossetti, Francesca Porcellati, Natalia Busciantella Ricci, et al.
Pageof 22

Showing results (191-200 of 220) with videos related to

Sort By:
Pageof 22
Diabetes|March 20, 2010
Mechanisms of insulin resistance after insulin-induced hypoglycemia in humans: the role of lipolysisPaola Lucidi, Paolo Rossetti, Francesca Porcellati, et al.
Journal of Clinical Neurophysiology : Official Publication of the American Electroencephalographic Society|March 10, 2000
Computer-assisted EEG monitoring during carotid endarterectomyF Minicucci, M Cursi, C Fornara, et al.
Diabetes|October 15, 2008
Portal vein glucose sensors do not play a major role in modulating physiological responses to insulin-induced hypoglycemia in humansPaolo Rossetti, Francesca Porcellati, Paola Lucidi, et al.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|April 8, 2014
Glargine metabolism over 24 h following its subcutaneous injection in patients with type 2 diabetes mellitus: a dose-response studyP Lucidi, F Porcellati, P Candeloro, et al.
Diabetes Care|January 14, 2021
Pharmacokinetic and Pharmacodynamic Head-to-Head Comparison of Clinical, Equivalent Doses of Insulin Glargine 300 units · mL<sup>-1</sup> and Insulin Degludec 100 units · mL<sup>-1</sup> in Type 1 DiabetesPaola Lucidi, Paola Candeloro, Patrizia Cioli, et al.
Diabetologia|December 13, 2006
Effect of the amino acid alanine on glucagon secretion in non-diabetic and type 1 diabetic subjects during hyperinsulinaemic euglycaemia, hypoglycaemia and post-hypoglycaemic hyperglycaemiaF Porcellati, S Pampanelli, P Rossetti, et al.
The Journal of Clinical Endocrinology and Metabolism|May 28, 2009
Short-term effects of the long-acting insulin analog detemir and human insulin on plasma levels of insulin-like growth factor-I and its binding proteins in humansFrancesca Porcellati, Paolo Rossetti, Paola Candeloro, et al.
Diabetes Care|March 21, 2025
The Modern Role of Basal Insulin in Advancing Therapy in People With Type 2 DiabetesGeremia B Bolli, Philip D Home, Francesca Porcellati, et al.
Diabetes Care|July 12, 2007
Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover studyFrancesca Porcellati, Paolo Rossetti, Natalia Ricci Busciantella, et al.
Diabetes|April 9, 2008
Effect of oral amino acids on counterregulatory responses and cognitive function during insulin-induced hypoglycemia in nondiabetic and type 1 diabetic peoplePaolo Rossetti, Francesca Porcellati, Natalia Busciantella Ricci, et al.
Pageof 22